Eton Pharmaceuticals, Inc. cash flow statement
In fiscal 2025, Eton Pharmaceuticals, Inc.'s operations generated $10.5m of cash; it spent $333,000 on capital projects, leaving free cash flow of $10.2m.
Cash flow statement
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −18 | −22 | −5 | 5 | 7 | 1 | 11 | 15 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 5 |
| Stock-based pay | 2 | 3 | 3 | 4 | 3 | 3 | 6 | 5 |
| Capital spending | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −19 | −22 | −5 | 5 | 7 | 1 | 10 | 15 |
| Free cash flow after stock pay | −21 | −25 | −8 | 1 | 4 | −2 | 5 | 10 |
| Shares issued | 0 | 29 | — | — | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 3 | −1 | 2 | 8 | 12 | −12 | 7 | 7 |
| Depreciation and amortisation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0 |
| Free cash flow | 3 | −1 | 2 | 8 | 12 | −12 | 7 | 7 |
| Free cash flow after stock pay | 1 | −2 | 1 | 6 | 11 | −13 | 6 | 6 |
Compare with peers
- Niagen Bioscience, Inc. cash flow
- Zevra Therapeutics, Inc. cash flow
- Natural Alternatives International Inc cash flow
- Heron Therapeutics, Inc. cash flow
- Rockwell Medical, Inc. cash flow
Head to head: ETON vs NAGEETON vs ZVRAETON vs NAII
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies